Vericel Corporation (VCEL)
| Market Cap | 2.06B +17.0% |
| Revenue (ttm) | 306.30M +23.0% |
| Net Income | 24.22M +240.8% |
| EPS | 0.47 +251.2% |
| Shares Out | 51.21M |
| PE Ratio | 85.72 |
| Forward PE | 61.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 223,874 |
| Open | 40.29 |
| Previous Close | 40.26 |
| Day's Range | 39.44 - 40.88 |
| 52-Week Range | 28.95 - 49.32 |
| Beta | 1.06 |
| Analysts | Strong Buy |
| Price Target | 59.71 (+48.5%) |
| Earnings Date | Nov 5, 2026 |
About VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use devic... [Read more]
Financial Performance
In 2025, Vericel's revenue was $276.26 million, an increase of 16.45% compared to the previous year's $237.22 million. Earnings were $16.52 million, an increase of 59.41%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for VCEL stock is "Strong Buy." The 12-month stock price target is $59.71, which is an increase of 48.50% from the latest price.
News
Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026
BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Co...
Vericel price target lowered to $52 from $58 at Truist
Truist lowered the firm’s price target on Vericel (VCEL) to $52 from $58 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
Vericel Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
MACI continues to drive robust growth through OUS expansion, new indications, and procedural innovation, supported by a larger, more productive sales force and commercial excellence initiatives. Burn Care is gaining momentum, aided by the BARDA contract, while strong margins and cash flow enable both shareholder returns and further business development.
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026
BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the C...
Vericel price target raised to $58 from $55 at TD Cowen
TD Cowen raised the firm’s price target on Vericel (VCEL) to $58 from $55 and keeps a Buy rating on the shares. The firm said its Q2 beat and raise…
Vericel Earnings Call Transcript: Q2 2026
Record Q2 revenue and profitability exceeded guidance, driven by strong MACI and Burn Care growth. Full-year guidance was raised, a $200 million share repurchase was announced, and significant cash generation supports ongoing investments and capital returns.
Vericel Slides: Q2 2026
Vericel has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Vericel Earnings release: Q2 2026
Vericel released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Vericel Quarterly report: Q2 2026
Vericel has published its Q2 2026 quarterly earnings report on July 30, 2026.
Vericel reports Q2 EPS 4c, consensus (3c)
Reports Q2 revenue $77.46M, consensus $72.69M. “The Company delivered excellent financial and business results in the second quarter as we continue to generate top-tier revenue and profit growth as we...
Vericel raises FY26 revenue view to $330M-$340M from $326M-$336M
Consensus $332.2M. Reaffirms full-year profitability guidance of gross margin of approximately 75% and adjusted EBITDA margin of approximately 27%.
Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Mill...
Vericel price target raised to $54 from $42 at Truist
Truist analyst Richard Newitter raised the firm’s price target on Vericel (VCEL) to $54 from $42 and keeps a Buy rating on the shares as part of a broader research…
Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
BURLINGTON, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Co...
Vericel Transcript: Truist Securities MedTech Conference 2026
Record growth in procedural volumes and revenue continues, with strong pricing power and no significant competitive threats anticipated. MACI Arthro adoption is expanding the market, and recent sales force expansion has been executed without disruption. Capital allocation priorities include business development and potential share buybacks.
Vericel Slides: FY 2026
Vericel has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 16, 2026.
Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Co...
Vericel price target raised to $70 from $64 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Vericel (VCEL) to $70 from $64 and keeps a Buy rating on the shares following the Q1 report.
Vericel reports Q1 EPS (12c), consensus (16c)
Reports Q1 revenue $68.4M, consensus $63.62M. Reports Q1 MACI revenue $56.4M, up from $46.3M last year. Reports Q1 burn care revenue up 91% vs. last year. “The Company delivered outstanding…
Vericel raises FY26 revenue guidance to $326M-$336M from $316M-$326M
Consensus $323.43M. The company also reaffirmed its FY26 profitability guidance of a gross margin of approximately 75% and an adjusted EBITDA margin of approximately 27%.
Vericel Earnings Call Transcript: Q1 2026
Record Q1 revenue and profit growth driven by MACI and Burn Care, with raised full-year guidance reflecting strong momentum and BARDA contract contributions. Expanded sales force and new manufacturing capacity support continued growth, while competitive and market conditions remain favorable.
Vericel Earnings release: Q1 2026
Vericel released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Vericel Slides: Q1 2026
Vericel has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Vericel Quarterly report: Q1 2026
Vericel has published its Q1 2026 quarterly earnings report on May 7, 2026.
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91%